Schenk Peter - Pulmol Abt, Landesklinikum Hochegg

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 24 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022)

Horst Olschewski,Ernst Eber,Brigitte Bucher,Klaus Hackner,Sabin Handzhiev,Konrad Hoetzenecker,Marco Idzko,Walter Klepetko, Gabor Kovacs, Bernd Lamprecht,Judith Löffler-Ragg,Michael Meilinger,

Wien Klin Wochenschr（2022）

Cited0Views0WOSBibtex

Can Simvastatin Reduce Copd Exacerbations? A Randomised Double-Blind Controlled Study

Peter Schenk,Alexander O Spiel, Felix Hüttinger, Micheline Gmeiner, Josefine Fugger, Martina Pichler, Gernot Pichler, Susanne Schmeikal, Wolfgang Janistyn, Stefan Schügerl, Constantin Sajdik,Harald Herkner

EUROPEAN RESPIRATORY JOURNAL（2021）

Cited14Views0WOSBibtex

Can Simvastatin reduce COPD exacerbations? A randomized double blind controlled study

Peter Schenk,Alexander Spiel, Felix Hüttinger, Markus Gmeiner, Josefine Fugger, Max Pichler, Gerhard Pichler, Susanne Schmeikal, Wolfgang Janistyn, Stefan Schügerl, Constantin Sajdik,Harald Herkner

Journal of Pulmonary Medicineno. 5 (2021): 2-2

Cited0Views0Bibtex

Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020)

Holger Flick,Britt-Madelaine Arns,Josef Bolitschek,Brigitte Bucher,Katharina Cima,Elisabeth Gingrich,Sabin Handzhiev,Maximilian Hochmair,Fritz Horak,Marco Idzko,Peter Jaksch, Gabor Kovacs,

WIENER KLINISCHE WOCHENSCHRIFT（2020）

Cited21Views0WOSBibtex

Results of the Austrian National Lung Cancer Audit

Otto C Burghuber,Klaus Kirchbacher,Andrea Mohn-Staudner,Maximilian Hochmair,Marie-Kathrin Breyer,Michael Studnicka,Michael Rolf Mueller,Petra Feurstein,Andrea Schrott, Bernd Lamprecht, Josef Eckmayr, Friedrich Renner,

CLINICAL MEDICINE INSIGHTS-ONCOLOGY（2020）

Cited2Views0WOSBibtex

Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC

Anna Buder,Maximilian J Hochmair, Sophia Schwab,Tatjana Bundalo,Peter Schenk,Peter Errhalt, Romana E Mikes,Gudrun Absenger,Kurt Patocka,Bernhard Baumgartner,Ulrike Setinek,Otto C Burghuber,

Journal of Thoracic Oncology（2018）

Cited54Views0WOSBibtex

P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC

Anna Buder,Maximilian Hochmair, Sophia Holzer, Andrea Mohn-Staudner,Peter Errhalt, Tatjana Bundalo,Peter Schenk,Ulrike Setinek,Otto Burghuber,Robert Pirker,Martin Filipits

Journal of Thoracic Oncologyno. 1 (2017)

Cited3Views0Bibtex

Association between EGFR T790M Mutation Copy Numbers in Cell -Free Plasma DNA and Response to Osimertinib in Advanced NSCLC

Anna Buder,Maximilian Hochmair,Sophia Holzer,Andrea Mohn-Staudner,Peter Errhalt, Tatjana Sundalo,Peter Schenk,Ulrike Setinek,Otto Burghuber,Robert Pirker,Martin Filipits

JOURNAL OF THORACIC ONCOLOGY（2017）

Cited0Views0Bibtex

P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC: Topic: EGFR Biomarkers

Anna Buder,Maximilian Hochmair,Sophia Holzer,Andrea Mohn-Staudner,Peter Errhalt,Tatjana Bundalo,Peter Schenk,Ulrike Setinek,Otto Chris Burghuber,Robert Pirker,Martin Filipits

Journal of Thoracic Oncology（2017）

Cited3Views0Bibtex

Muskeldystrophie - what else

Gernot Pichler,Gernot Kuhteubl, Samy Mazhar,Peter Schenk

WIENER KLINISCHE WOCHENSCHRIFTno. 19-20 (2017): 750-750

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn